FREDUN · Fredun Pharmaceuticals Ltd · Biotechnology & Drugs
FREDUN · Fredun Pharmaceuticals Ltd · Biotechnology & Drugs
As of 06 Nov close
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹228 Cr
Revenue YoY
PAT YoY
+93.9%
Operating margin
Revenue, last 5 quarters
P/E (TTM)
P/B
8.8
P/S (TTM)
3.3
Sector P/E
33.6
Dividend yield
+0.0%
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| FREDUN (this stock) | 52.8 | 8.8 | +5.8% | +15.4% | 0.8 | +0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- mediumcorporate actionthehindubusinessline.com· 22 Sept 2026, 03:14 pmFredun Pharma acquires 26% stake in Goodman Vetcare Private Limited
- unknownthehindubusinessline.com· 08 Sept 2026, 08:39 pmFredun Pharmaceuticals has acquired drugmaker USV’s pet-wellness brand Furlicks
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
Governance disclosures
AI-generatedNo governance disclosures identified in FREDUN's filed documents yet.